EXCERPT:
Charles River is divesting its manufacturing business to GI Partners and its discovery assets to IQVIA. The move reshapes the competitive landscape for CROs and CDMOs supporting early and late-phase drug development.
CONTENT:
Charles River Laboratories announced the sale of its CDMO business to GI Partners and its discovery services assets to IQVIA — a significant structural move that narrows Charles River’s focus while redistributing major capabilities across the industry.
For those working in the CRO space, this is worth paying attention to. IQVIA absorbing discovery assets adds significant scientific depth to what has historically been a data and late-phase powerhouse. GI Partners acquiring the CDMO business suggests a private equity bet on manufacturing services demand continuing to grow independent of a large CRO umbrella.
What it means practically: the CRO landscape is consolidating and specializing simultaneously. Full-service models are being stress-tested while focused players — particularly in manufacturing and advanced modalities — are attracting investment. If you’re working at a CRO, understanding where your organization fits in this shifting map matters.